Trump hints at ACA compromise

In his first interview since winning the presidency, President-elect Donald Trump told the Wall Street Journal he favors keep certain popular portions of the Affordable Care Act (ACA), though he campaigned on a promise to fully repeal the law.

What he said he will keep are the provisions banning insurers from denying coverage based on preexisting conditions and allowing children to stay on their parents’ health plans until they reach the age of 26.

“I like those very much,” Trump said.

Their inclusion in his healthcare plans isn’t much of a surprise. The House Republicans’ latest ACA replacement plan called for maintaining “continuous coverage” for people with preexisting conditions, though that protection would be forfeited if someone opted not to buy insurance during a one-time open enrollment period.

Trump offered little else in terms of concrete details on health policy, saying the ACA could be “amended, or repealed and replaced.” His softer tone came after his Nov. 10 White House meeting with President Barack Obama, who Trump said encouraged him to reconsider a full repeal.

“I told him I will look at his suggestions, and out of respect, I will do that,” Trump said.

Trump’s transition team updated the incoming administration’s health care policy goals two days after winning the election. Short on specifics, the list does include repealing the ACA, using state-run high-risk pools to cover sicker patients, and “maximizing flexibility” for Medicaid, which may refer to his campaign proposal to turn it into a state block grant program.

“The administration recognizes that the problems with the U.S. healthcare system did not begin withand will not end with the repeal ofthe ACA,” the transition team’s list of goals said.

Trump has tapped Andrew Bremberg, a former HHS official under George W. Bush, to lead the new administration’s transition plans for the agency.

An earlier study by the Commonwealth Fund and the RAND Corporation said the effects of repealing the ACA would cause nearly 19.7 million people to lose coverage and increase the average out-of-pocket costs on the individual market to $4,700 per person. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.